Cereno Scientific AB — Investor Relations & Filings

Cereno Scientific is a clinical-stage biotechnology company developing disease-modifying therapeutics for rare cardiovascular and pulmonary diseases. The company's pipeline focuses on epigenetic modulation and includes a portfolio of Histone Deacetylase (HDAC) inhibitors in clinical development. These candidates are designed to address the root mechanisms of complex diseases. In the preclinical stage, the company is advancing assets such as CS585, a novel prostacyclin (IP) receptor agonist. The strategic focus on rare diseases targets underserved patient populations with significant unmet medical needs, aiming to provide high treatment value and potentially enable shorter development timelines.